Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis

Circulation

Volumn 120, Issue 24, 2009, Pages 2470-2477

  Onoue, Kenji ^a   Uemura, Shiro ^a   Takeda, Yukiji ^a   Somekawa, Satoshi ^a   Iwama, Hajime ^a   Imagawa, Keiichi ^a   Nishida, Taku ^a   Morikawa, Yoshinobu ^a   Takemoto, Yasuhiro ^a   Asai, Osamu ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a   Ishigami, Kenichi ^a   Nakatani, Kimihiko ^a   Kawata, Hiroyuki ^a   Horii, Manabu ^a   Nakajima, Tamio ^a   Akai, Yasuhiro ^a   Iwano, Masayuki ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary disease; Growth substances; Heart failure; Kidney

Indexed keywords

APOLIPOPROTEIN E; FMS LIKE TYROSINE KINASE 1; MESSENGER RNA; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; GROWTH HORMONE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEPHRECTOMY; PLACENTAL HORMONES; RANDOM ALLOCATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 73349107133     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.867929     Document Type: Article

References (37)

1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease. Kidney Int. 2005;67:2089-2100.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-2047. (Pubitemid 350074801)
3. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156-163. (Pubitemid 47012510)
4. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl): S16-S23.
5. Ninomiya T, Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population. Kidney Int. 2005;68:228-236.
6. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction and renal dysfunction. Ann Intern Med. 2002;137:563-570.
7. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.
8. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;27:1245-1250.
9. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelen-kofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
11. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805.
12. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/ Flt-1). Angiogenesis. 2006;9:225-230.
13. Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111: 2828-2836.
14. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.
17. Yoshimoto S, Nakatani K, Iwano M, Asai O, Samejima K, Sakan H, Terada M, Harada K, Akai Y, Shiiki H, Nose M, Saito Y. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am J Kidney Dis. 2007;50:47-58.
18. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol. 2003;14:2466-2474.
19. Egfjord M, Langhoff E, Daugaard H, Olgaard K. Increased clearance rate of prednisone in the isolated perfused liver of uremic rats. Nephron. 1987;45:53-58.
20. Lewin E, Colstrup H, Pless V, Ladefoged J, Olgaard K. A model of reversible uremia employing isogenic kidney transplantation in the rat. Scand J Urol Nephrol. 1993;27:115-120.
21. Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach F. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low density lipoprotein receptor-deficient mice. Circulation. 2003;107:1033-1039.
22. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709.
23. Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA. 1993;90:8915-8919.
24. Helske S, Vuorela P, Carpén O, Hornig C, Weich H, Halmesmäki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod. 2001;7:205-210.
25. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001;97:785-791.
26. Thomas S, Vanuystel J, Gruden G, Rodríguez V, Burt D, Gnudi L, Hartley B, Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol. 2000;11:1236-1243.
27. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583.
28. Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. J Biol Chem. 1996;271:1729-1734.
29. Pilarczyk K, Sattler KJ, Galili O, Versari D, Olson ML, Meyer FB, Zhu XY, Lerman LO, Lerman A. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabili-zation. Atherosclerosis. 2008;196:333-340.
30. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S. Placental growth factor reconstitutes hema-topoiesis by recruiting VEGFR1( + ) stem cells from bone-marrow micro-environment. Nat Med. 2002;8:841-849.
31. Iwama H, Uemura S, Naya N, Imagawa K, Takemoto Y, Asai O, Onoue K, Okayama S, Somekawa S, Kida Y, Takeda Y, Nakatani K, Takaoka M, Kawata H, Horii M, Nakajima T, Doi N, Saito Y. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol. 2006;47:1559-1567.
32. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
33. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
34. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003;88:2348-2351.
35. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
36. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and pro-teinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
37. Vogel C, Bauer A, Wiesnet M, Preissner KT, Schaper W, Marti HH, Fischer S. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J Cell Physiol. 2007;212:236-243.